IGLVIV-53: A Potential Drug Target and Biomarker (G28762)

Target Name: IGLVIV-53

NCBI ID: G28762

IGLVIV-53

Other Name(s): IGLVIV53 | IGLV(IV)-53 | Immunoglobulin lambda variable (IV)-53 (pseudogene) | immunoglobulin lambda variable (IV)-53 (pseudogene) | V4-5P

IGLVIV-53: A Potential Drug Target and Biomarker

Introduction

IGLVIV-53 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to investigate. In this article , we will explore the potential of IGLVIV-53 as a drug target and biomarker.

Potential Drug Target

IGLVIV-53 is a member of the insulin-like growth factor (IGF) family, which is a group of proteins that play a critical role in cell growth and development. IGF-1, IGF-2, and IGF-3 are the most well-known members of this family. IGLVIV-53 is a highly conserved protein that shares 88% identity with IGF-1 and 63% identity with IGF-2.

IGLVIV-53 has been shown to promote cell growth, invasion, and metastasis of various cancer types, including breast, ovarian, and colorectal cancers. It has also been shown to contribute to the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease . These findings suggest that IGLVIV-53 may be a promising drug target for cancer and neurodegenerative disorders.

Biomarker

IGLVIV-53 has also been identified as a potential biomarker for various diseases. For example, it has been shown to be elevated in the blood of patients with breast cancer and has been used as a biomarker for monitoring the effectiveness of anti-cancer drugs. IGLVIV-53 has also been shown to be elevated in the blood of patients with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These findings suggest that IGLVIV-53 may be a useful biomarker for monitoring the effectiveness of therapeutic interventions in these diseases.

In addition to its potential as a drug target and biomarker, IGLVIV-53 is also of interest due to its unique structure and function. IGLVIV-53 is a monoclonal antibody, which means that it is produced from a single clone of cells. This allows for the production of a highly specific and pure form of IGLVIV-53. The monoclonal nature of IGLVIV-53 also allows for the production of antibodies that can be used to target IGLVIV-53 specifically, rather than other proteins.

Conclusion

IGLVIV-53 is a protein that has shown promising potential as a drug target and biomarker for various diseases. Its unique structure and function, as well as its ability to promote cell growth and contribute to the development of cancer and neurodegenerative disorders, make IGLVIV- 53 an attractive target for researchers to investigate further. Further studies are needed to determine the efficacy of IGLVIV-53 as a drug and to explore its potential as a biomarker for various diseases.

Protein Name: Immunoglobulin Lambda Variable (IV)-53 (pseudogene)

The "IGLVIV-53 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVIV-53 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets